BCMA-T cell bispecific antibodies for the treatment of multiple myeloma
Klaus Strein was a co-founder of the Swiss biotech startup EngMab and Dr. Erich Hunziker the seed investor. Based on a license for the so-called 2+1 T cell bispecific antibody format, a 2+1 format BCMA x CD3 bsAb has been developed.
In 2016 EngMab was acquired by Celgene. First clinical results for the BCMAxCD3 bsAb were presented at the 61st ASH Annual Meeting in 2019.
